Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PDT-NEO-immunother

Financiado

Generation of tumor neoantigens with photodynamic therapy: a new strategy for an...

Generation of tumor neoantigens with photodynamic therapy: a new strategy for anticancer vaccines to fight head and neck cancer Immunogenic cell death (ICD) is a regulated cell death that stimulates the immune responses resulting in the establishment of long- term immunological memory. ICD alert the immune system by tumor-associated antigens and tumor neoa... ver más

30/11/2025

UGent

176K€

Presupuesto del proyecto: 176K€

Líder del proyecto

UNIVERSITEIT GENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-23

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

UGent

175.92K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CAN-IT-BARRIERS Disruption of systemic and microenvironmental barriers to i... 3M€ Cerrado

NeoIDC Neoantigen Identification with Dendritic Cell Reprogramming 150K€ Cerrado

Mel-Immune An integrative genetic approach for the exploration of melan... 3M€ Cerrado

INCEPTOR Investigate the mode of action ofInvestigate the mode of act... 192K€ Cerrado

MIMIC Molecular mimicry as a key parameter shaping T cell immunity 2M€ Cerrado

ICD-Cancer Immunogenic cell death (ICD) in the cancer-immune dialogue 3M€ Cerrado

Duración del proyecto: 32 meses Fecha Inicio: 2023-03-23
Fecha Fin: 2025-11-30

Líder del proyecto

UNIVERSITEIT GENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 176K€

Descripción del proyecto Immunogenic cell death (ICD) is a regulated cell death that stimulates the immune responses resulting in the establishment of long- term immunological memory. ICD alert the immune system by tumor-associated antigens and tumor neoantigens (i.e., antigenicity) and releasing immunostimulant mediators such as the damage- associated molecular patterns (DAMPs, adjuvanticity). ICD can be efficiently induced by photodynamic therapy (PDT). Our key hypothesis is that PDT based on clinically approved and in-house developed photosensitizers, which are efficient in several murine cancer models, will induce ICD in head and neck squamous cell carcinomas (HNSCCs) which are the fourth most frequent types of cancer in men. Specifically, we aim to demonstrate for the first time that PDT will modulate the immunogenicity of dying HNSCC cells not only by releasing DAMPs but also by increasing antigenicity of dying HNSCC cells by affecting their landscape of antigens. This will lead to the activation of the innate and adaptive immune system and to the improvement of anti-cancer therapy of HNSCC patients. For the study, we will exploit HNSCC cells derived from patients’ biopsies, representing an ideal preclinical model that incorporates heterogeneity of tumors observed in patients. In this way, we will obtain the data required to support future clinical trials based on PDT. Indeed, the ultimate goal of the neoantigen identification is to pave the way for developing patient-specific targeted vaccine therapies.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores